Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969643 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-LIV1A in Breast Cancer Patients
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
NCT01969643 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 290 participants.
The verdict
NCT01969643, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
Study Summary
This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
Interventions
- DRUG Trastuzumab
- DRUG ladiratuzumab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2013-10-22 |
| Est. Completion | 2023-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01969643
The ClinicalTrials.gov registry entry for NCT01969643 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT01969643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01969643 about?
NCT01969643 is a clinical study titled "A Safety Study of SGN-LIV1A in Breast Cancer Patients". This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
What is the current status of trial NCT01969643?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2013-10-22. Estimated completion is 2023-02-04.
What interventions are being tested in trial NCT01969643?
The interventions under investigation include: Trastuzumab (DRUG), ladiratuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT01969643?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.